Literature DB >> 10367357

Shiga/verocytotoxins and Shiga/verotoxigenic Escherichia coli in animals.

J Mainil1.   

Abstract

Vero/Shiga toxins (VT/Stx) have an A-B structure: the A subunit carries the enzymatic activity and the B subunit binds the toxin to the membrane receptor (Gb3 or Gb4). The VT/Stx inhibit protein synthesis in the target eucaryotic cells, mainly the endothelial cells of blood vessels. The VT/Stx are subdivided into two families. VT1/Stx1 is a homogeneous family of toxins identical to the Stx of Shigella dysenteriae. VT2/Stx2 is a more heterogeneous family of toxins more distantly related to this Stx toxin. The VT2/Stx2 variants can be distinguished by the polymerase chain reaction (PCR) and/or the reaction with monoclonal antibodies. The VT/Stx-producing Escherichia coli are also subdivided into two main groups on the basis of the presence or absence of additional properties: the enterohaemorrhagic E. coli (EHEC) induce the formation of attaching/effacing lesions and carry a 60 MD plasmid encoding a specific haemolysin (the enterohaemolysin); the vero/shiga-toxigenic E. coli (VTEC/STEC) do not show these properties. The EHEC are isolated from humans and ruminants, especially young calves. They are associated with haemorrhagic enterocolitis and its sequelae in humans, the haemolytic-uraemic syndrome (HUS). The VT/Stx play a role in the occurrence of blood in the faeces and in the HUS by their action on the endothelial cells of blood vessels in the intestinal submucosa and in the renal glomeruli, after resorption through the intestinal walls. The VTEC/STEC are isolated from piglets, calves and humans. In recently weaned piglets, they cause the oedema disease, an enterotoxaemia characterized by subcutaneous, mesenteric and cerebral oedemas, with nervous disorders as main clinical signs. The oedema disease is the consequence of the action of the VT/Stx on the endothelial cells of blood vessels in various organs. In calves and humans, the role in disease of VTEC/STEC is controversial, but they could be associated with some cases of diarrhoea and HUS. The case of the O157:H7 EHEC which are present in healthy cattle of various ages, but are highly virulent for humans is of special interest. The potential zoonotic aspect of VT/Stx-producing E. coli infections in animals is detailed chapter by chapter. Prophylaxis of these infections by vaccination is the subject of the discussion on the future of the research studies on these pathogenic bacteria.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10367357

Source DB:  PubMed          Journal:  Vet Res        ISSN: 0928-4249            Impact factor:   3.683


  25 in total

1.  A newly discovered verotoxin variant, VT2g, produced by bovine verocytotoxigenic Escherichia coli.

Authors:  P H M Leung; J S M Peiris; W W S Ng; R M Robins-Browne; K A Bettelheim; W C Yam
Journal:  Appl Environ Microbiol       Date:  2003-12       Impact factor: 4.792

2.  Inactivation of shiga toxin-producing Escherichia coli (STEC) and degradation and removal of cellulose from STEC surfaces by using selected enzymatic and chemical treatments.

Authors:  Yoen Ju Park; Jinru Chen
Journal:  Appl Environ Microbiol       Date:  2011-10-14       Impact factor: 4.792

3.  Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection.

Authors:  Jean Mukherjee; Kerry Chios; Dianne Fishwild; Deborah Hudson; Susan O'Donnell; Stephen M Rich; Arthur Donohue-Rolfe; Saul Tzipori
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

4.  Subtilase cytotoxin-coding genes in verotoxin-producing Escherichia coli strains from sheep and goats differ from those from cattle.

Authors:  José A Orden; Pilar Horcajo; Ricardo de la Fuente; José A Ruiz-Santa-Quiteria; Gustavo Domínguez-Bernal; Javier Carrión
Journal:  Appl Environ Microbiol       Date:  2011-09-30       Impact factor: 4.792

Review 5.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

6.  Shedding patterns of verocytotoxin-producing Escherichia coli strains in a cohort of calves and their dams on a Scottish beef farm.

Authors:  D J Shaw; C Jenkins; M C Pearce; T Cheasty; G J Gunn; G Dougan; H R Smith; M E J Woolhouse; G Frankel
Journal:  Appl Environ Microbiol       Date:  2004-12       Impact factor: 4.792

Review 7.  Initial adherence of EPEC, EHEC and VTEC to host cells.

Authors:  Marjorie Bardiau; Mihai Szalo; Jacques G Mainil
Journal:  Vet Res       Date:  2010-04-29       Impact factor: 3.683

8.  Shiga toxin-producing Escherichia coli in Central Greece: prevalence and virulence genes of O157:H7 and non-O157 in animal feces, vegetables, and humans.

Authors:  O Pinaka; S Pournaras; V Mouchtouri; E Plakokefalos; A Katsiaflaka; F Kolokythopoulou; E Barboutsi; N Bitsolas; C Hadjichristodoulou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-05-16       Impact factor: 3.267

9.  2F3 monoclonal antibody recognizes the O26 O-antigen moiety of the lipopolysaccharide of enterohemorrhagic Escherichia coli strain 4276.

Authors:  I M Szalo; B Taminiau; F Goffaux; V Pirson; J McCappin; H J Ball; J G Mainil
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

10.  Putative adhesins of enteropathogenic and enterohemorrhagic Escherichia coli of serogroup O26 isolated from humans and cattle.

Authors:  Marjorie Bardiau; Sabrina Labrozzo; Jacques G Mainil
Journal:  J Clin Microbiol       Date:  2009-04-29       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.